← All trials
NCT05534165
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2022
- Primary completion
- Jan 31, 2023
- Completion date
- Feb 28, 2023
- First posted
- Sep 9, 2022
- Last posted
- Sep 9, 2022
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- McGill UniversityLead sponsor
- Unity Health TorontoCollaborator
- CIHR Canadian HIV Trials NetworkCollaborator
- McGill UniversityCollaborator
- McGill UniversitySponsor investigator
- University of TorontoCollaborator
- University of British ColumbiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.